Objective:To evaluate the clinical efficacy of Qiyu Qinghua Decoction on proteinuria in chronic kidney disease (CKD) of the spleen and kidney qi deficiency type and its effect on inflammatory cytokines. Methods72 patients with proteinuria in CKD of the spleen and kidney qi deficiency type were randomly assigned into treatment group and control group, 36 patients in each group. Conventional therapy in Western medicine was given in both groups, in addition, the treatment group was treated with Qiyu Qinghua Decoction, and the control group received Shenyan Kangfu Tablets. Both groups were treated for 6 months. The clinical efficacy and the changes in the scores of syndromes in traditional Chinese medicine (TCM), 24-hour urinary protein quantification (UPro), renal function, serum albumin, blood lipids as well as inflammatory cytokines (hs-CRP, TNF-α and IL-6) were observed.  Results:①=1\*GB3The total effective rate was 77.8% and 52.8% in the treatment group and the control group, respectively, and the clinical efficacy in the treatment group was superior to that in the control group (P<0.05). ②After treatment, the scores of edema, poor appetite and abdominal distention and the total score of TCM syndrome decreased in both groups (P<0.05), and the scores of lumbar spine ache and fatigue also decreased in the treatment group (P<0.05). The scores of lumbar spine ache and fatigue and the total score of TCM syndrome were significantly lower in the treatment group than in the control group after treatment (P<0.05). ③=3\*GB3After treatment, the 24h UPro decreased significantly in both groups (P<0.05); the 24h UPro,Scr and eGFR improved in the treatment group compared to the control group (P<0.05). ④=4\*GB3After treatment, the levels of hs-CRP, TNF-α and IL-6 decreased in both groups (P<0.05); and the levels were lower in the treatment group than in the control group (P<0.05).  Conclusion:Qiyu Qinghua Decoction shows improved clinical efficacy in treating proteinuria in CKD of the spleen and kidney qi deficiency type, improves clinical symptoms of the patients, reduces the excretion of urinary protein and delays the deterioration of renal function. It is possible that the drug protects the kidney by reducing the expression of inflammatory cytokines.